Efficacy and Tolerability of Levetiracetam in Parkinson Disease Patients With Levodopa-Induced Dyskinesia

Abstract

Objectives: 

This open-label study was performed to evaluate the efficacy and tolerability of levetiracetam for levodopa-induced dyskinesia and its effect on motor functioning and quality of life in Parkinson disease (PD) patients.

Methods: 

PD patients with moderate to severe dyskinesia were enrolled in the study. PD medications were unchanged during the study, and levetiracetam was slowly titrated up to a maximum dosage of 3000 mg/d over a 2-month period.

Results: 

There were 9 patients with a mean age of 65 years and mean disease duration of 13 years. Forty-four percent of the subjects withdrew before the end of the study due to adverse events, primarily worsening of PD symptoms and sleepiness. Of the remaining 5 subjects, 1 subject continued levetiracetam after the study with mild improvement in dyskinesia and 4 discontinued levetiracetam due to worsening of PD symptoms and sleepiness.

Conclusions: 

Levetiracetam is not well tolerated in PD patients with levodopa-induced dyskinesia resulting in worsening of PD symptoms, intolerable somnolence, and worsening of dyskinesia in most patients.